423 related articles for article (PubMed ID: 33053560)
1. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
2. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
[TBL] [Abstract][Full Text] [Related]
6. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
de Gooijer CJ; van der Noort V; Stigt JA; Baas P; Biesma B; Cornelissen R; van Walree N; van Heemst RC; Soud MY; Groen HJM; den Brekel AJS; Buikhuisen WA; Bootsma GP; Dammeijer F; van Tinteren H; Lalezari F; Aerts JG; Burgers JA;
Lancet Respir Med; 2021 Jun; 9(6):585-592. PubMed ID: 33515500
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
[TBL] [Abstract][Full Text] [Related]
8. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
Mutlu H; Gündüz S; Karaca H; Büyükçelik A; Cihan YB; Erden A; Akca Z; Coşkun HS
Med Oncol; 2014 Aug; 31(8):74. PubMed ID: 24958517
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; De Vincenzo F; Giordano L; Cordua N; D'Antonio F; Santoro A
Lung Cancer; 2020 Apr; 142():132-137. PubMed ID: 32102735
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL
Lancet Oncol; 2021 Oct; 22(10):1438-1447. PubMed ID: 34499874
[TBL] [Abstract][Full Text] [Related]
12. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
[TBL] [Abstract][Full Text] [Related]
13. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
Lee CW; Murray N; Anderson H; Rao SC; Bishop W
Lung Cancer; 2009 Jun; 64(3):308-13. PubMed ID: 19004520
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
Jänne PA; Simon GR; Langer CJ; Taub RN; Dowlati A; Fidias P; Monberg M; Obasaju C; Kindler H
J Clin Oncol; 2008 Mar; 26(9):1465-71. PubMed ID: 18349397
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
Simon GR; Verschraegen CF; Jänne PA; Langer CJ; Dowlati A; Gadgeel SM; Kelly K; Kalemkerian GP; Traynor AM; Peng G; Gill J; Obasaju CK; Kindler HL
J Clin Oncol; 2008 Jul; 26(21):3567-72. PubMed ID: 18640937
[TBL] [Abstract][Full Text] [Related]
19. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
de Lima VA; Sørensen JB
Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
Favaretto AG; Aversa SM; Paccagnella A; Manzini Vde P; Palmisano V; Oniga F; Stefani M; Rea F; Bortolotti L; Loreggian L; Monfardini S
Cancer; 2003 Jun; 97(11):2791-7. PubMed ID: 12767092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]